Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

33.23 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,495
Open 33.23
Bid (Size) 32.45 (1)
Ask (Size) 33.05 (1)
Prev. Close 33.23
Today's Range 33.23 - 33.23
52wk Range 2.100 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy. 
Via Stocktwits
Why Summit Therapeutics Rocketed Double-Digits Today
Via The Motley Fool
Topics World Trade
Exposures Tariff

Performance

YTD
+81.1%
+81.1%
1 Month
+60.6%
+60.6%
3 Month
+41.3%
+41.3%
6 Month
+65.9%
+65.9%
1 Year
+790.9%
+790.9%

More News

Read More
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Via Benzinga
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
Via Investor's Business Daily
Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics Inc.
Via Business Wire
This Company's Co-CEOs Just Bought More Shares. Should You?
Via The Motley Fool
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
Via Benzinga
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX
Via Stocktwits
Topics Animal Testing
Exposures Animal Testing Product Safety
Gold Related Large-Cap Stocks Outperformed In One Of The Most Volatile Weeks (Apr 7-Apr 11): Are These In Your Portfolio?
Via Benzinga
3 Magnificent Stocks That Could Double or More by 2030
Via The Motley Fool
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets
Via The Motley Fool
Topics ETFs
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
Via Benzinga
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade
Via The Motley Fool
Topics Government
Exposures Political
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Economy Tariff
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Via The Motley Fool
Topics Government World Trade
Exposures COVID-19 Political Product Safety
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Topics Intellectual Property Retirement
Exposures Intellectual Property Pension
Why Summit Therapeutics Stock Slipped Today
Via The Motley Fool
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
Via Benzinga
Is Summit Therapeutics a Millionaire Maker?
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
This Unstoppable Biotech Stock Just Became an Even Better Buy
Via The Motley Fool
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
From Summit Therapeutics Inc.
Via Business Wire
Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Via Benzinga

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 33.23
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 04/23/25 04:15 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 3.24B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.